Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 23 of 272 for:    Betamethasone

Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris (TRIANGLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02004574
Recruitment Status : Completed
First Posted : December 9, 2013
Last Update Posted : June 4, 2014
Sponsor:
Information provided by (Responsible Party):
Jooheung Lee, Samsung Medical Center

Brief Summary:

The combination of calcipotriol and betamethasone dipropionate used in an ointment formulation (Daivobet® ointment) has shown to have an excellent efficacy and safety in the short-term and long-term management of psoriasis vulgaris. A newly developed gel formulation (Xamiol® gel) of calcipotriol and betamethasone dipropionate has recently been approved and marketed in Korea as a topical treatment of moderate to severe scalp psoriasis and non-scalp psoriasis vulgaris.

Xamiol® gel, the investigational product (IP) used in this study, prevents keratinization by normalizing the reproduction cycle of skin cells. It also relieves itching associated with psoriasis. Xamiol® gel was initially approved for treatment of moderate to severe scalp psoriasis and its label was extended to non-scalp psoriasis vulgaris in October 2012.

Since patient compliance is one of the important factors in achieving effective outcomes in the treatment of psoriasis, the once daily dosing of Xamiol® gel is expected to enhance compliance and treatment outcomes as well as to provide a safe and effective therapeutic option.


Condition or disease Intervention/treatment Phase
Psoriasis Vulgaris Drug: Calcipotriol/betamethasone dipropionate gel Phase 4

Detailed Description:

Psoriasis is a disease difficult to cure and is usually recurrent and therefore, a continued management is crucial. An evidence-based approach is important for appropriate treatments of patient with psoriasis. However, there is a lack of response data for the topical treatments in Asian patients with psoriasis, and no treatment guidelines available. Therefore, routine topical treatments, instead of patient-specific treatments, are usually applied, which may result in treatment failure. In this regard, it is imperative to conduct a study to assess topical treatments in Korean patients with psoriasis vulgaris in terms of efficacy and side effects.

Furthermore, psoriasis patients in Korea, mostly small plaque types, may exhibit different disease activities and response outcomes and accordingly require different treatment options as compared to Western populations whose dominant psoriasis type is large plaque type. Thus, a study in Korean patients with psoriasis may reveal an interesting finding.

In order to investigate optimal maintenance regimens for the topical treatment of Korean patients with psoriasis vulgaris, we are planning this study which evaluates the efficacy of three 8-week maintenance regimens containing Xamiol® gel (PRN treatment group, Continuous treatment group and Twice weekly treatment group) in patients who have become "Responder" after 8-week induction therapy with Xamiol® gel ("Responder").

The primary objective of this study is to evaluate the percentages of "Responder"* at week 16, as assessed by Investigator's Global Assessment of Disease Severity (IGA), in three different 8-week maintenance regimens of Xamiol® gel after 8-week induction treatment with Xamiol® gel in patients with psoriasis vulgaris.

* Responder is defined as subjects with "clear" or "almost clear" according to IGA.

Secondary study objectives is to evaluate efficacy, % of Relapse and time to Relapse, PGA, Patient Compliance, Safety and Quality of Life (DLQI and TSQM) in three arms with calcipotriol/betamethasone dipropionate combination gel treatment in Korean patients with chronic plaque psoriasis of the body.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 201 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Investigator Initiated Study for Optimal Maintenance Treatment With Calcipotriol /Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris
Study Start Date : October 2013
Actual Primary Completion Date : June 2014
Actual Study Completion Date : June 2014


Arm Intervention/treatment
Experimental: PRN treatment
Group 1: PRN treatment Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel) once daily as needed (PRN)
Drug: Calcipotriol/betamethasone dipropionate gel
All enrolled subjects will receive Xamiol® gel once daily for 8 weeks during the induction period and then will be assessed according to IGA at the end of 8-week induction period. Those subjects determined to be "Responder" by IGA will be randomized to one of the following three treatment groups and they will continue their therapy with randomized maintenance regimens for the duration of additional 8 weeks.
Other Name: Xamiol gel

Experimental: Continuous treatment
Group 2: Continuous treatment Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel)once daily
Drug: Calcipotriol/betamethasone dipropionate gel
All enrolled subjects will receive Xamiol® gel once daily for 8 weeks during the induction period and then will be assessed according to IGA at the end of 8-week induction period. Those subjects determined to be "Responder" by IGA will be randomized to one of the following three treatment groups and they will continue their therapy with randomized maintenance regimens for the duration of additional 8 weeks.
Other Name: Xamiol gel

Experimental: Weekends treatment
Group 3: Weekends treatment (twice weekly) Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel) once daily at weekends (on Saturdays and Sundays)
Drug: Calcipotriol/betamethasone dipropionate gel
All enrolled subjects will receive Xamiol® gel once daily for 8 weeks during the induction period and then will be assessed according to IGA at the end of 8-week induction period. Those subjects determined to be "Responder" by IGA will be randomized to one of the following three treatment groups and they will continue their therapy with randomized maintenance regimens for the duration of additional 8 weeks.
Other Name: Xamiol gel




Primary Outcome Measures :
  1. Percentage of "Responder" (subjects with a grade of "clear" or "almost clear") according to IGA at Week 16 [ Time Frame: Week 16 ]
    The primary objective of this study is to evaluate the percentages of "Responder"* at week 16, as assessed by Investigator's Global Assessment of Disease Severity (IGA), in three different 8-week maintenance regimens of Xamiol® gel after 8-week induction treatment with Xamiol® gel in patients with psoriasis vulgaris.


Secondary Outcome Measures :
  1. Investigator's global assessment of disease severity [ Time Frame: Week 0, 4, 8, 12 and 16 ]
    To evaluate the change of disease severity assessed by IGA in induction treatment phase and compare the IGA disease severity of three different maintenance regimens in the maintenance treatment phase.

  2. Percentage of disease relapse [ Time Frame: Week 0, 4, 8, 12 and 16 ]
    To evaluate descriptive statistics of three different regimens in the maintenance treatment phase and compare percentage of relapse in threee different regimens.

  3. Patient's global assessment of disease severity [ Time Frame: Week 0, 4, 8, 12 and 16 ]
    To evaluate the change of disease severity assessed by PGA in induction treatment phase and compare the PGA disease severity of three different maintenance regimens in the maintenance treatment phase.

  4. Change in Psoriasis Area and Severity Index (PASI) score from Baseline to Week [ Time Frame: Week 0, 4, 8, 12 and 16 ]
    To evaluate the change of PASI in induction treatment phase and compare the PASI of three different maintenance regimens in the maintenance treatment phase.

  5. Percent of subjects achieving a 75% improvement in the Psoriasis Area and Severity Index (PASI) score [ Time Frame: Week 0, 4, 8, 12 and 16 ]
    To evaluate the change of PASI75 from week 4 to week 8 in induction treatment phase and compare PASI75 in three different regimens in the maintenance treatment phase.

  6. Time to relapse [ Time Frame: Week 0, 4, 8, 12 and 16 ]
    To evaluate descriptive statistics of three different regimens in the maintenance treatment phase and compare the time to relapse in threee different regimens.


Other Outcome Measures:
  1. Subject's Compliance [ Time Frame: Week 4, 8, 12 and 16 ]
    To evaluate subject's compliance by subject's diary, interview, used IP dose and evaluate descriptive statistics for them.

  2. Dermatology Life Quality Index [ Time Frame: Week 0, 4, 8, 12 and 16 ]
    To evaluate the change of DLQI score in induction treatment phase and evaluate change rate of week 8, week 12 and week 16 compared with baseline in the maintenance treatment phase.

  3. Treatment Satisfaction Questionnaire for Medication [ Time Frame: Week 8 and 16 ]
    To evaluated descriptive statistics for TSQM score of week 8 in the induction treatment phase and evaluate change rate of week 8, week 16 and from week 8 to week 16 in the maintenance treatment phase.

  4. Other treatment after completion of study [ Time Frame: Week 16 ]
    To evaluate descriptive statistics for used other medication after study completion.

  5. Laboratory assessment [ Time Frame: Week 0, 8, 16 and 18 ]

    To evaluate the reported values(normal/abnormal) as follows.

    : To evaluate change of reported values from baseline to week 8 in induction treatment phase and compare reported values of week 8 and week 16 in three different regimens in the maintenance treatment phase.


  6. SAEs [ Time Frame: Week 0, 4, 8, 12, 16 and 18 ]
    To evaluate the number of occurrance(subject-based) in each treatment phase and regimen and compare the number of occurrance in three difference regimens in the maintenance treatment phase.

  7. AEs [ Time Frame: Week 0, 4, 8, 12, 16 and 18 ]
    To evaluate the number of occurrance(subject-based) in each treatment phase and regimen and compare the number of occurrance in three difference regimens in the maintenance treatment phase.

  8. ADRs [ Time Frame: Week 0, 4, 8, 12, 16 and 18 ]
    To evaluate the number of occurrance(subject-based) in each treatment phase and regimen and compare the number of occurrance in three difference regimens in the maintenance treatment phase.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female subjects aged 19 years and above
  2. Clinical diagnosis of stable psoriasis vulgaris of at least 4 weeks duration involving the non-scalp regions of the body (trunk and/or limbs) amenable to treatment with a maximum of 100 g of topical medication per week at screening
  3. An investigator's global assessment of disease severity(IGA) of at least mild on the body (trunk and/or limbs) at Day 0 (Baseline)
  4. Signed written informed consent prior to performance of any study-specific procedures or assessments, and must be willing to comply with treatment and follow up
  5. Able to communicate with the investigator and understand and comply with the requirements of the study
  6. Women of childbearing potential must have a negative pregnancy test and must use adequate contraception during the treatment phase of the study and for at least 1 week after the last application of study medication

Exclusion Criteria:

  1. Body surface area (BSA) > 10 % or Psoriasis Area and Severity Index (PASI) > 10 at baseline

    * The palm of one hand is approximately 1 percent of the body surface area

  2. Subjects with unstable forms of psoriasis including guttate, erythrodermic, exfoliative and pustular psoriasis, or psoriatic arthritis
  3. Subjects with known disorders of calcium metabolism/hypercalcemia
  4. Subjects with hypersensitivity to the active substances or to any of the excipients of the investigational products
  5. Systemic treatment with biological therapies with a possible effect on psoriasis vulgaris within the following time periods prior to baseline visit

    • etanercept - within 4 weeks prior to baseline
    • adalimumab, alefacept, infliximab - within 2 months prior to baseline
    • ustekinumab - within 4 months prior to baseline
    • investigational product - within 4 weeks/5 half-lives (whichever is longer) prior to baseline
  6. Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g., corticosteroids, retinoids, methotrexate, cyclosporine and other immunosuppressants) within 4 weeks prior to baseline visit
  7. Phototherapy within the following time periods prior to baseline visit

    • PUVA or Grenz ray - within 4 weeks
    • UV-B - within 2 weeks
  8. Any topical treatment of the trunk and/or limbs (except for emollients) within 2 weeks prior to baseline visit
  9. Topical treatment for other relevant skin disorders on the face and flexures (e.g., facial and flexural psoriasis, eczema) with class 1- 5 corticosteroids or vitamin D analogues within 2 weeks prior to baseline visit
  10. Topical treatment for other relevant skin disorders on the scalp (e.g. scalp psoriasis) with class 1-5 corticosteroids, vitamin D analogues within 2 weeks prior to baseline visit
  11. Subjects with severe renal insufficiency
  12. Subjects with severe hepatic disorders
  13. Subjects with a confounding skin condition or disorders against psoriasis evaluation
  14. Subjects with viral (e.g. herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections on the treatment area
  15. Subjects with skin manifestations in relation to tuberculosis or syphilis on the treatment area
  16. Subjects with perioral dermatitis, atrophic skin, striae atrophicae on the treatment area
  17. Subjects with fragility of skin veins, ichthyosis on the treatment area
  18. Subjects with acne vulgaris, rosacea, wounds, ulcers, perianal and genital pruritus on the treatment area
  19. Planned initiation of, or changes to, concomitant medication that could affect psoriasis vulgaris (e.g. beta blockers, anti-malarials, lithium, ACE inhibitors) during the study
  20. Pregnant or lactating female subjects
  21. Subjects who are planning a pregnancy during the entire study period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02004574


Locations
Layout table for location information
Korea, Republic of
Samsung Medical Center
Gangnam-gu, Seoul, Korea, Republic of, 135-710
Sponsors and Collaborators
Jooheung Lee
Investigators
Layout table for investigator information
Study Chair: Joo-Heung Lee, MD Samsung Medical Center

Publications of Results:

Layout table for additonal information
Responsible Party: Jooheung Lee, Professor, Samsung Medical Center
ClinicalTrials.gov Identifier: NCT02004574     History of Changes
Other Study ID Numbers: KSPLK 2013-01
First Posted: December 9, 2013    Key Record Dates
Last Update Posted: June 4, 2014
Last Verified: June 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Betamethasone
Betamethasone Valerate
Betamethasone-17,21-dipropionate
Betamethasone benzoate
Betamethasone sodium phosphate
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Calcitriol
Calcipotriene
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Calcium-Regulating Hormones and Agents
Calcium Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Vitamins
Micronutrients
Nutrients
Growth Substances
Bone Density Conservation Agents